ArticleCurrent Alzheimer research2025
Network Pharmacology of miR-146a-5p as a Potential Anti-Inflammatory Agent in Preventing Alzheimer's Disease.
Article in Current Alzheimer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlzheimer's disease is expressed as chronic neuroinflammation in the brain, which results in neuronal dysfunction, aberrant protein folding, and declining cognitive abilities. miR-146a-5p is a potent anti-inflammatory agent that can attenuate several inflammatory diseases and promote wound healing. Our research aimed to utilize network pharmacology to elucidate the therapeutic potential of miR-146a-5p in treating Alzheimer's disease using a biocomputational approach.
methodAlzheimer's disease genes were extracted from DisGeNET, OMIM, and GeneCards databases. At the same time, miR-146a-5p candidate genes were sourced from four prediction databases: miRDB, miRWalk, miRNet, and TargetScan.
resultsThe overlap between miR-146a-5p and Alzheimer's disease genes was established using STRING, with a score greater than 0.9, revealing a total of 157 nodes in the compound-target disease network. DISCUSSIONS: Pathway enrichment analysis further revealed key candidate genes associated with Alzheimer's, including those involved in neuronal death, leukocyte migration, and axon development. EGFR, IL6, NFKB1, TLR4, CXCL8, FN1, CXCR4, and BCL2 were pinpointed as the top 8 key candidate genes of miR-146a-5p. Between these key candidate genes, the miR-146a-5p Regulatory Network also demonstrated that miR-146a-5p downregulates EGFR and CXCR4. Furthermore, this research revealed the regulatory network of miR-146a-5p, which modulates the transcriptional activities of IL6, NFKB1, TLR4, CXCL8, FN1, and BCL2.
conclusionTherefore, the current network pharmacology study explored the principal mechanism behind the anti-inflammatory effects of miR-146a-5p in treating Alzheimer's disease, and potentially to be applied to other neurodegenerative diseases.
Indexed as
Identifiers
40916429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.